Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Q3 2021 Earnings Conference Call November 4, 2021 5:00 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors David Arthur - Director, CEO Mark Rosenblum - CFO Nadeem Mirza - Senior Vice President, Clinical Development Daniela Santiesteban - Director of Corporate Development Conference Call Participants Ahu Demir - Ladenburg Aydin Huseynov - Benchmark Mike King - HC Wainwright Hunter Diamond - Diamond Equity Operator Thank you for standing by. And w ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36812 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or oth ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Q2 2021 Earnings Conference Call August 5, 2021 10:00 AM ET Company Participants Jason Rando - Investor Relations, Executive Vice President, Chief Operating Officer, Tiberend Strategic Advisors David Arthur - Director & Chief Executive Officer Mark Rosenblum - Chief Financial Officer Nadeem Mirza - Senior Vice President, Clinical Development Daniela Santiesteban - Director, Corporate Development Conference Call Participants Aydin Huseynov - Benchmark Hunter Diamo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36812 SALARIUS PHARMACEUTICALS, INC. (Former name, former address and former fiscal year, If changed since las ...

Company Overview 3Q 2021 © 2021 Salarius Pharmaceuticals, Inc. Non Confidential Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement in this presentation that is not a historical fact is a forward-looking statement. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication o ...

Company Overview 2Q 2021 © 2021 Salarius Pharmaceuticals, Inc. Non Confidential Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement in this presentation that is not a historical fact is a forward-looking statement. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36812 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other j ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Q4 2020 Earnings Conference Call March 18, 2021 4:30 AM ET Company Participants Jason Rando - EVP & COO, Tiberend Strategic Advisors David Arthur - CEO, President & Director Mark Rosenblum - EVP, Finance & CFO Nadeem Mirza - SVP, Clinical Development Daniela Santiesteban - Director, Research and Business Development Conference Call Participants Wangzhi Li - Ladenburg Thalmann & Co. Aydin Huseynov - The Benchmark Company Hunter Diamond - Diamond Equity Research Op ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or Other Jurisdiction of Incorporation or Organization) Delaware 46-5087339 (I.R.S. Employer Identification No.) ———————–––––————————— FORM 10-K ———————————— (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Pe ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Jason Rando - Tiberend Strategic Adviser David Arthur - Director & Chief Executive Officer Mark Rosenblum - Chief Financial Officer Daniela Santiesteban - Director, Research and Business Development Conference Call Participants Aydin Huseynov - Benchmark Hunter Diamond - Diamond Equity Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2020 Sal ...